Investors & Media

We are driven to develop meaningful therapies for patients while creating value for stockholders.

Investors & Media

Corporate Profile

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion is advancing its portfolio of differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs include olinciguat in Phase 2 development for sickle cell disease, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Presentation

We are seeking to unlock the full therapeutic potential of the nitric oxide-cGMP pathway to design differentiated next-generation sGC stimulators for serious and orphan diseases. Watch our video to learn more about this fundamental pathway and how sGC stimulation works.